Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paris M Kollis"'
Autor:
Jake Nowicki, Michael P Brown, Tessa Gargett, Lisa M Ebert, Nga T H Truong, Paris M Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Briony L Gliddon, Melinda N Tea, Rebecca Ormsby, Santosh Poonnoose, Orazio Vittorio, David S Ziegler, Stuart M Pitson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Aggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity. Effective treatments for primary brain tumors are limited,
Externí odkaz:
https://doaj.org/article/aeb6b5a8c73041bf87654aafeab489d5
Autor:
Lisa M Ebert, Wenbo Yu, Tessa Gargett, John Toubia, Paris M Kollis, Melinda N Tea, Brenton W Ebert, Cedric Bardy, Mark van den Hurk, Claudine S Bonder, Jim Manavis, Kathleen S Ensbey, Mariana Oksdath Mansilla, Kaitlin G Scheer, Sally L Perrin, Rebecca J Ormsby, Santosh Poonnoose, Barbara Koszyca, Stuart M Pitson, Bryan W Day, Guillermo A Gomez, Michael P Brown
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 10, Pp n/a-n/a (2020)
Abstract Objectives Targeted immunotherapies such as chimeric antigen receptor (CAR)‐T cells are emerging as attractive treatment options for glioblastoma, but rely on identification of a suitable tumor antigen. We validated a new target antigen fo
Externí odkaz:
https://doaj.org/article/d95e2e808e74470a9794a5b6b9f9e770
Autor:
Paris M. Kollis, Lisa M. Ebert, John Toubia, Cameron R. Bastow, Rebecca J. Ormsby, Santosh I. Poonnoose, Sakthi Lenin, Melinda N. Tea, Stuart M. Pitson, Guillermo A. Gomez, Michael P. Brown, Tessa Gargett
Publikováno v:
Frontiers in Immunology. 13
Refereed/Peer-reviewed Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades. T-cell-based immunotherapies such as immune-checkpoint inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed7811ed12e8cc0f927dd6db1a4dad1
https://doi.org/10.3389/fimmu.2022.850226
https://doi.org/10.3389/fimmu.2022.850226
Autor:
Tessa Gargett, Lisa M Ebert, Nga T H Truong, Paris M Kollis, Kristyna Sedivakova, Wenbo Yu, Erica C F Yeo, Nicole L Wittwer, Briony L Gliddon, Melinda N Tea, Rebecca Ormsby, Santosh Poonnoose, Jake Nowicki, Orazio Vittorio, David S Ziegler, Stuart M Pitson, Michael P Brown
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005187
BackgroundAggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the potential for severe toxicity. Effective treatments for primary brain tumors are limited, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db02d9834284e5bfabdf812eeafd4f68
https://doi.org/10.1136/jitc-2022-005187
https://doi.org/10.1136/jitc-2022-005187